Provided by Tiger Trade Technology Pte. Ltd.

Serina Therapeutics, Inc.

2.42
-0.0400-1.63%
Volume:23.12K
Turnover:56.00K
Market Cap:61.47M
PE:-1.25
High:2.50
Open:2.40
Low:2.38
Close:2.46
52wk High:5.83
52wk Low:1.22
Shares:25.40M
Float Shares:11.48M
Volume Ratio:0.79
T/O Rate:0.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9304
EPS(LYR):-1.9100
ROE:-207.94%
ROA:-92.30%
PB:3.28
PE(LYR):-1.27

Loading ...

Serina Therapeutics Signs Deal for up to USD 25 Million Unregistered Common Stock Sales to Roth Principal Investments

Reuters
·
Aug 27

Serina Therapeutics - Enters Stock Purchase Agreement with Roth Principal Investments on Aug 21, 2026 - SEC Filing

THOMSON REUTERS
·
Aug 27

Serina Therapeutics - Offers up to 12,500,000 Shares of Common Stock by Roth Principal Investments - SEC Filing

THOMSON REUTERS
·
Aug 25

Serina Therapeutics: Buy Rating Reiterated, $11 Price Target Maintained on Strong SER-252 Clinical Progress

TIPRANKS
·
Aug 19

Serina Therapeutics, Inc Q2 Operating Expenses USD 6.784 Million

THOMSON REUTERS
·
Aug 14

Serina Therapeutics Q2 FY26 Net Loss Narrows to $6.36 Million; Revenue Falls to no Grant Revenue

Reuters
·
Aug 14

Serina Therapeutics Posts Investor Deck Outlining POZ Platform, Lead Parkinson’s Candidate Ser-252 Phase 1b Study

Reuters
·
Jul 29

Serina Therapeutics to Join BTIG Virtual Biotechnology Conference Investor Meetings

Reuters
·
Jul 24

Serina Therapeutics Director Simon Farrell Files Initial Beneficial Ownership Statement

Reuters
·
Jul 24

Serina Therapeutics CEO Steve Ledger Base Salary Rises to $500,000 Under Amended Employment Deal

Reuters
·
Jul 24

Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of Ser-252 for Advanced Parkinson’s Disease

THOMSON REUTERS
·
Jul 23

Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease

GlobeNewswire
·
Jul 23

Serina Therapeutics Appoints Trevi CCO Farrell Simon to Board

Reuters
·
Jul 23

Serina Therapeutics Appoints Farrell Simon to Its Board of Directors

THOMSON REUTERS
·
Jul 23

Serina Says Panel Clears Dosing More Patients in Phase 1b Trial of SER-252 in Parkinson's Disease

MT Newswires Live
·
Jul 10

Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1B Registrational Trial of Ser-252 for Advanced Parkinson’s Disease

THOMSON REUTERS
·
Jul 10

Serina Therapeutics Director Stephen K. Brannan Acquires 1,000 Common Shares Worth $2,030

Reuters
·
Jul 10

Seres Therapeutics' Phase 1 Trial of SER-155 Meets Primary Endpoint; Shares Rise Pre-Bell

MT Newswires Live
·
Jul 08

Seres Therapeutics announces top-line results from SER-155 trial

TIPRANKS
·
Jul 08

Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment

GlobeNewswire
·
Jul 08